MicroTex is a Research and Partnership Hub developing advanced technologies for intra-target microdosing, which allows scientists to test multiple drugs at very small doses directly to the affected tissue. This provides early insight into how drugs act, helping to inform decisions and advance the drug development pipeline and allows for scientists to focus resources on the most promising treatments. Initially, MicroTex is focusing on two target areas, inflammation in the distal lung, and microbial keratitis, corneal infections of the eye and a leading cause of blindness worldwide. The aim is to develop technologies which can help identify and develop drugs more effectively and efficiently, helping to bring new treatment to patients all over the world. Based at The University of Edinburgh’s Institute for Regeneration and Repair, within the Baillie Gifford Pandemic Science Hub, MicroTex is a collaboration involving engineers, scientists and clinicians from The University of Edinburgh, Heriot-Watt University and University of Bath. Funded by the Engineering and Physical Science Research Council (EPSRC) What is MicroTex? MicroTex is a Research and Partnership Hub developing advanced technologies for intra-target microdosing, which allows scientists to test multiple drugs at very small doses directly to the affected tissue.Based at The University of Edinburgh’s Institute for Regeneration and Repair, within the Baillie Gifford Pandemic Science Hub, MicroTex is a collaboration involving engineers, scientists and clinicians from The University of Edinburgh, Heriot-Watt University and University of Bath. View media transcript Every day around the world, millions of people are being infected by infection and inflammation in many parts of the human body. And antimicrobial resistance is one of the biggest challenges to modern medicine. What if we could find a new way, a faster, better way to develop drugs, to take them to patient groups around the world? Microtech is developing advanced technologies that enable a new approach called intra target microdosing, in which scientists test tiny amounts of novel medicines on tiny areas of tissue directly at the site of disease, then measure the effect. By measuring what happens at the target tissue, researchers can make better decisions earlier and focus resources on the most promising treatments. So Microtech is all about that and focusing on two disease areas. One is antimicroial resistance information in the lungs, and the other one is in coneourtitis, and meanness bindssness in the front of the eye. Infections affecting the cornea, which is the clear layer at the front of the eye, are an ophthalmic emergency and a leading cause of blindness worldwide. These infections are treated with eye drops, but tears and blinking wash away most of the medicine before it can be absorbed, reducing its effectiveness. Micro techs are developing a tiny patch that delivers medicine directly to the cornea while measuring how the tissue responds to the treatment. This will help drugs to get to where they are most needed to actually treat the infection and can help researchers understand much earlier if the treatments are working. So some lung infections are investigated with bronchoscopy, where we use a bronchoscope, a small, thin camera tube that's inserted down into the deep parts of the lung so we can take samples. However, the lung is very complex, and the anatomy means that it's very difficult for us to reliably get into these deep parts of the lung. At Micro techs, we're developing a bronchoscopy system that uses robotics and artificial intelligence so we can more reliably and accurately get into those deep dark areas of the lung and go back there time and time again to the same exact spot. This will help us understand how our treatments are affecting that part of the lung and ultimately will hopefully help our patients. Research is always stronger when it's driven by clinical needs and the live experience of patients who are experiencing lung and eye infections. In micro techs, we are constantly making decisions about risks and benefits to patients. These decisions are not purely technical. They also require an understanding of what matters to patients and society. So by involving patients and the public in everything we do, we ensure that the research that we develop is not only scientifically rigorous, but also socially relevant and meaningful. Micro Techs is a multi million pound collaboration involving engineers, scientists and clinicians at the University of Edinburgh, Marriott Wart University, and the University of Bath. It is developing advanced tools to make new drug development faster, smarter, and more precise. So why does it matter? It means we can find new effective treatments earlier, faster, reduce costly failures, improve decision making to bring these therapies to patients. It will also reduce but remove the need for animal testing. Related links MicroTex website MicroTex LinkedIn This article was published on Tuesday 6 October 2026